	US 11,986,452 B2
	Methods of reducing the risk of heart failure
Paresh Soni, Mystic, CT (US)
Assigned to AMARIN PHARMACEUTICALS IRELAND LIMITED, Dublin (IE)
Filed by Amarin Pharmaceuticals Ireland Limited, Dublin (IE)
Filed on Apr. 19, 2022, as Appl. No. 17/723,598.
Claims priority of provisional application 63/177,723, filed on Apr. 21, 2021.
Prior Publication US 2022/0347148 A1, Nov. 3, 2022
Int. Cl. A61K 31/232 (2006.01); A61P 9/10 (2006.01)

CPC A61K 31/232 (2013.01) [A61P 9/10 (2018.01)]

18 Claims

1. A method of reducing risk of heart failure in a subject having a baseline triglyceride level of at least 135 mg/dL and a baseline serum and/or plasma eicosapentaenoic acid (EPA) level of about 26 μg/mL, the method comprising administering to said subject about 4 g of ethyl icosapentate per day for a period effective to increase said subject's EPA level to at least about 104 μg/mL.